We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.

International Symposium on Amyloidosis

Mayo Clinic

Poster Abstracts - TREATMENTS OF ATTR

Tafamidis 80 mg is more likely to improve disease measures than placebo in patients with transthyretin amyloid cardiomyopathy PC90 (#2)

Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study PC91 (#9)

Survival in a real-world cohort of patients with mixed phenotype transthyretin amyloidosis treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey PC107 (#10)

Safety and efficacy of tafamidis in Chinese patients with transthyretin amyloid cardiomyopathy PC92 (#13)

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy PC93 (#14)

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy PC94 (#15)

Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction PC95 (#17)

SGLT-2- inhibitors in patients with cardiac wildtype ATTR- amyloidosis PC96 (#41)

Comparison of Combination Therapy (Tafamidis Plus Silencer) vs. Tafamidis Monotherapy in Transthyretin Amyloid Cardiomyopathy: Single Center Retrospective Cohort Study PC97 (#42)

Genotype vs phenotype and access to treatment in patients with hereditary transthyretin amyloidosis from a reference center in Brazil PC98 (#77)

Treating Transthyretin Amyloidosis with CRISPR/Cas9 via LNP Delivery for in vivo TTR Knockdown PC99 (#82)

Open-label treatment data from the Swedish SveaTTR registry support the efficacy of diflunisal for hereditary transthyretin amyloidosis. PC100 (#116)

Single Center Study of Long-Term Outcomes in ATTR-CM Patients treated with Tafamidis vs Acoramidis: Early findings at the dawn of a new era. PC101 (#118)

Association between Patient Characteristics and Serum Neurofilament Light Chain Level in Patients with Transthyretin-Related Amyloid Cardiomyopathy PC102 (#133)

Enabling the development of serum TTR as a biomarker for treatment of ATTR amyloidosis PC103 (#151)

Design and rationale for MAGNITUDE, a phase 3, randomized, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) PC104 (#152)

Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease  PC105 (#171)

Neuropathy Impairment and Nutritional Status with Eplontersen in Patients with Hereditary Transthyretin-Mediated Amyloidosis PC106 (#174)

History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B PC108 (#176)

A unified analysis of the impact of rapid TTR knockdown by RNAi therapeutics across transthyretin-mediated (ATTR) amyloidosis studies PC109 (#182)

Rationale and Design of ACT-EARLY, the Acoramidis Transthyretin Amyloidosis Prevention Trial PC110 (#190)

Arginine, as a possible amino acid for prevention of ATTR amyloidosis PC111 (#196)

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients PC112 (#202)

Magnitude and timing of change in monitoring parameters for transthyretin amyloidosis cardiomyopathy patients treated and untreated with tafamidis PC113 (#217)

Transthyretin amyloidosis cardiomyopathy disease staging systems for patients treated with tafamidis therapy PC114 (#218)

Determinants guiding clinical decision-making for treatment initiation in transthyretin amyloidosis cardiomyopathy patients in Canada PC115 (#219)

ALXN2220: targeted immune activation in patients undergoing antibody-mediated cardiac ATTR amyloid depletion PC116 (#227)

Reduction of amyloid deposition by patisiran －Evaluation by gastroduodenal biopsy and amyloid 11C-Pittsburgh compound B PET PC117 (#228)

Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis in Patients With the V30M TTR Variant and Early-Onset or Late-Onset Disease PC118 (#230)

Single-center one-year outcome of Vutrisiran treatment in hereditary transthyretin amyloidosis PC119 (#233)

Racial/Ethnic Differences in Treatment Utilization for ATTR Amyloidosis PC120 (#241)

Safety and efficacy of levosimendan in patients with cardiac amyloidosis PC121 (#245)

Higher Risk of Mortality in Previously Hospitalized Patients: Insights from ATTRibute-CM PC122 (#279)

Prediction of cardiac ATTR depletion by NI006 using mechanistic PK/PD modeling PC123 (#291)

Treatment-related Early Increase in Serum TTR is Associated with Lower Cardiovascular Mortality in ATTR-CM: Insights from ATTRibute-CM PC124 (#292)

Improved Health-Related Quality of Life in Acoramidis-Treated Patients with ATTR-CM, Demonstrated by Improvements in KCCQ Scores PC125 (#295)

ATTRibute-CM: ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD PC126 (#300)

Acoramidis significantly improves NT-proBNP indices that indicate ATTR-CM disease progression and predict subsequent mortality: Insights from the ATTRibute-CM Study  PC127 (#303)

Acoramidis May Improve Cardiac Function and Promote Regression in ATTR-CM: Data From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy PC128 (#315)

Safety of Direct Current Cardioversion Without Routine Transesophageal Echocardiography in Patients with Cardiac Amyloidosis PC129 (#317)

Early Increase in Serum Transthyretin Level is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM PC130 (#321)

Arrhythmia burden and progression in ATTR-CM patients treated and untreated with tafamidis PC131 (#344)

Acoramidis Improves Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy PC132 (#349)

Disease progression in patients with wild-type transthyretin cardiomyopathy on treatment with tafamidis: prevalence and clinical correlates. PC133 (#374)

ATTR V30M Nephropathy: Implications of switching anti-amyloid agents PC134 (#396)

Early tolerance of SGLT2i therapy in patients with ATTR V30M amyloidosis: staging and scoring for a standard of care evaluation across different clinical phenotypes PC135 (#399)

Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis: An EQ-5D Analysis From the ATTRibute-CM Study PC136 (#402)

SGLT2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: A Propensity Score-Matched Analysis PC137 (#409)

THE AMYLOIDOSIS FORUM: Five Years of Progress for the Public-Private Partnership to Advance Drug Development for Amyloidosis PC138 (#414)

A phase III randomized study of doxycycline and tauroursodeoxycholic acid (Doxy/TUDCA) plus standard supportive therapy versus standard supportive therapy alone in cardiac amyloidosis caused by transthyretin PC139 (#441)

Regression of amyloid load in subcutaneous fat tissue of hereditary transthyretin amyloidosis patients during treatment with patisiran PC140 (#465)

Establishing amyloidosis clinics at a university hospital in the Northwest of Germany PC141 (#498)

Descriptive characteristics of patients diagnosed with transthyretin amyloidosis (ATTR) in the Medicare fee-for-service and commercial populations PC142 (#518)

Clinical Trial Design of AT-02 Phase 2 Open Label Extension Study in Systemic Amyloidosis PC143 (#519)

Predictors of early mortality after initiation of tafamidis therapy PC144 (#538)

Comparison of treatment responders versus non-responders in transthyretin amyloid cardiomyopathy PC145 (#540)